Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clopidogrel
89%
Colombians
84%
Acute Coronary Syndrome
73%
CYP2C19
63%
Polymorphism
47%
Coronary Artery Disease
42%
Paraoxonase 1 (PON1)
36%
Q192R Polymorphism
36%
Pharmacogenetic Study
36%
Clopidogrel Therapy
36%
Pharmacological Analysis
36%
Pacientes
36%
Disease Susceptibility
36%
Origen
36%
Terapia
36%
Genetic Variants
30%
Adverse Drug Reaction
24%
CYP2C19 Polymorphism
19%
Coding Region
19%
Allele Frequency
19%
Q192R
15%
School of Medicine
15%
Inter-individual Variability
14%
Platelets
14%
Non-genetic Factors
10%
Clopidogrel Response
10%
Undergraduate Medical Students
10%
Gain-of-function
10%
Health Sciences
10%
European Medicines Agency
10%
Loss Function
10%
Adverse Reactions
10%
Odds Ratio
10%
Confidence Interval
10%
Intronic Variant
9%
New Haplotype
9%
P2Y12 Receptor Blockers
9%
Pathogenic mutations
9%
Personalized Medicine
9%
Adverse Effects
9%
Treatment Response
9%
Linkage Disequilibrium
9%
Polymorphic Alleles
9%
Clinical Outcomes
9%
Bleeding
9%
Single nucleotide Variant
9%
Regulatory Region
9%
Pharmacogenes
9%
Susceptible Response
5%
Pharmacokinetics
5%
Adenosine Diphosphate
5%
Cerebrovascular Disease
5%
Serious Adverse Events
5%
Internal Medicine Residency
5%
Adverse Cardiovascular Events
5%
Anti-atherogenic Properties
5%
Therapeutic Outcome
5%
Enzymatic Activity
5%
Therapeutic Effect
5%
PFA-200
5%
Single nucleotide Polymorphism
5%
High On-treatment Platelet Reactivity
5%
Antithrombotic Effect
5%
Functional Characterization
5%
Management Scheme
5%
Platelet Aggregation
5%
Lipid Peroxides
5%
Molecular Markers
5%
Drug Metabolism
5%
GnomAD
5%
Platelet Function
5%
Antiplatelet Activity
5%
Antiplatelet Drugs
5%
CYP2C19*17
5%
Health Sciences Programme
5%
Drug Response
5%
Promoter Region
5%
Patient Identification
5%
High Platelet Reactivity
5%
Am(III)
5%
Clot Formation
5%
Number of Drugs
5%
Bleeding Risk
5%
Phase I Metabolism
5%
CYP2C
5%
Asian Population
5%
Biotransformation
5%
Peripheral Vascular Disease
5%
Knowledge Gaps
5%
Functional Analysis
5%
Research Seedbed
5%
High Incidence
5%
Pharmacogenetics
5%
Platelet Inhibition
5%
Patients at Risk
5%
Rare Allele
5%
Potential Response
5%
Chemoreceptor
5%
Clopidogrel Metabolism
5%
Response to Therapy
5%
Clinical Response
5%
Therapeutic Failure
5%
Complex Allele
5%
Pharmacological Management
5%
Active Metabolite
5%
Pharmacodynamics
5%
Therapeutic Response
5%
Genotype
5%
Latin American
5%
Public Database
5%
Decreased Susceptibility
5%
Dominant Model
5%
Allele Distribution
5%
Disease Response
5%
Glycoprotein
5%
Genetic Model
5%
High-density Lipoprotein Cholesterol (HDL-C)
5%
Increased Vulnerability
5%
Biochemistry, Genetics and Molecular Biology
Clopidogrel
100%
Allele
80%
Pharmacogenetic Testing
73%
CYP2C19
58%
Aryldialkylphosphatase
36%
Paraoxonase
36%
Genetic Divergence
25%
Platelet
21%
Gene Frequency
17%
Haplotype
16%
Single-Nucleotide Polymorphism
11%
Platelet Reactivity
9%
Genetic Determinism
9%
Promoter Region
9%
Coding Region
9%
Metabolic Pathway
9%
P2Y12
7%
Regulatory Region
7%
Gene Linkage Disequilibrium
7%
Lipid Peroxide
5%
Thrombocyte Function
5%
High-Density Lipoprotein
5%
Glycoprotein
5%
Genetic Model
5%
Neuroscience
Clopidogrel
100%
Acute Coronary Syndrome
73%
Cytochrome P450 2C19
58%
Aryldialkylphosphatase 1
36%
Platelet
36%
Allele Frequency
17%
Haplotype
16%
Metabolic Pathway
13%
Single-Nucleotide Polymorphism
11%
Coding Region
9%
Promoter Region
9%
Purinergic P2Y12 Receptor
7%
Regulatory Region
7%
Adverse Effect
7%
Linkage Disequilibrium
7%
Glycoprotein
5%
Lipid Peroxide
5%
High-Density Lipoprotein
5%